KR102474489B1 - 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포 - Google Patents

안구 질환을 치료하기 위한 abcb5(+) 줄기 세포 Download PDF

Info

Publication number
KR102474489B1
KR102474489B1 KR1020227011673A KR20227011673A KR102474489B1 KR 102474489 B1 KR102474489 B1 KR 102474489B1 KR 1020227011673 A KR1020227011673 A KR 1020227011673A KR 20227011673 A KR20227011673 A KR 20227011673A KR 102474489 B1 KR102474489 B1 KR 102474489B1
Authority
KR
South Korea
Prior art keywords
abcb5
cells
cell
stem cells
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227011673A
Other languages
English (en)
Korean (ko)
Other versions
KR20220048048A (ko
Inventor
마르쿠스 하. 프랑크
나타샤 와이. 프랭크
브루스 크샌더
파라스케비 에비 코로보우
Original Assignee
칠드런'즈 메디컬 센터 코포레이션
더 셰펜스 아이 리써치 인스티튜트, 인크.
브이에이 보스톤 헬스케어 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칠드런'즈 메디컬 센터 코포레이션, 더 셰펜스 아이 리써치 인스티튜트, 인크., 브이에이 보스톤 헬스케어 시스템 filed Critical 칠드런'즈 메디컬 센터 코포레이션
Publication of KR20220048048A publication Critical patent/KR20220048048A/ko
Application granted granted Critical
Publication of KR102474489B1 publication Critical patent/KR102474489B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227011673A 2013-02-19 2014-02-19 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포 Active KR102474489B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361766424P 2013-02-19 2013-02-19
US61/766,424 2013-02-19
PCT/US2014/017076 WO2014130518A1 (en) 2013-02-19 2014-02-19 Abcb5(+) stem cells for treating ocular disease
KR1020157025733A KR102385934B1 (ko) 2013-02-19 2014-02-19 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157025733A Division KR102385934B1 (ko) 2013-02-19 2014-02-19 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포

Publications (2)

Publication Number Publication Date
KR20220048048A KR20220048048A (ko) 2022-04-19
KR102474489B1 true KR102474489B1 (ko) 2022-12-06

Family

ID=51391751

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227011673A Active KR102474489B1 (ko) 2013-02-19 2014-02-19 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포
KR1020157025733A Active KR102385934B1 (ko) 2013-02-19 2014-02-19 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157025733A Active KR102385934B1 (ko) 2013-02-19 2014-02-19 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포

Country Status (9)

Country Link
US (3) US9801912B2 (https=)
EP (2) EP2964238B1 (https=)
JP (2) JP7027026B2 (https=)
KR (2) KR102474489B1 (https=)
AU (1) AU2014219026B2 (https=)
CA (1) CA2901931C (https=)
DK (1) DK2964238T3 (https=)
ES (1) ES2860573T3 (https=)
WO (1) WO2014130518A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290028B1 (en) 2000-06-05 2009-12-23 The Brigham And Women's Hospital, Inc. A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF
HUE059011T2 (hu) 2006-05-31 2022-09-28 Childrens Medical Center Immunmodulátorként szolgáló ABC5-pozitív mezenchimális õssejtek
DK2155248T3 (en) 2007-04-12 2015-09-14 Brigham & Womens Hospital Targeting abcb5 for cancer therapy
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
PT3130923T (pt) 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Métodos terapêuticos relacionados com células estaminais
AU2014219026B2 (en) 2013-02-19 2018-11-29 Children's Medical Center Corporation ABCB5(+) stem cells for treating ocular disease
EP4008369A1 (en) 2013-05-10 2022-06-08 Children's Medical Center Corporation Wound healing and tissue engineering
EP4036228A1 (en) 2015-11-13 2022-08-03 Avellino Lab USA, Inc. Methods for the treatment of corneal dystrophies
WO2019210109A1 (en) 2018-04-25 2019-10-31 Children's Medical Center Corporation Abcb5 ligands and substrates
WO2020021535A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
EP3823646A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
JP7586811B2 (ja) 2018-07-22 2024-11-19 ミノヴィア セラピューティクス リミテッド 腎臓疾患のミトコンドリア増強療法
AU2019311859B2 (en) * 2018-07-22 2025-12-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
KR20210145178A (ko) * 2019-04-01 2021-12-01 스템사이트 오와이 Abcg2-양성 각막 주변부 줄기 세포를 수득 또는 유지하는 방법
WO2021092564A1 (en) * 2019-11-07 2021-05-14 Massachusetts Eye And Ear Infirmary Cultivated autologous limbal epithelial cell (calec) transplantation
EP3842079A1 (en) * 2019-12-24 2021-06-30 Universiteit Antwerpen Ophthalmological device for the treatment of lscd and substrate for use in same
US20230148432A1 (en) * 2020-03-30 2023-05-11 Children's Medical Center Corporation Use of stem cells for treatment of excessive inflammation
BR112022019609A2 (pt) 2020-03-31 2022-11-29 Minovia Therapeutics Ltd Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
US20240335562A1 (en) * 2021-08-04 2024-10-10 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders
KR20230129828A (ko) 2022-03-02 2023-09-11 포항공과대학교 산학협력단 안구 후방 질환 또는 손상의 예방 또는 치료용 조성물
KR102913194B1 (ko) 2022-03-03 2026-01-19 서울대학교병원 안구건조증 또는 마이봄샘 기능장애의 예방, 개선, 또는 치료용 조성물
CN115074368B (zh) * 2022-06-09 2023-08-08 澳门科技大学 一种耐药型类风湿性关节炎动物模型的构建及其应用
WO2025090565A1 (en) * 2023-10-23 2025-05-01 The Children's Medical Center Corporation Abcb5-targeted stem cell reprogramming and anti-aging strategies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080003206A1 (en) * 2006-05-31 2008-01-03 The Brigham And Women's Hospital, Inc. ABCB5 positive mesenchymal stem cells as immunomodulators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434075A (en) 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
ATE439849T1 (de) 1996-04-19 2009-09-15 Osiris Therapeutics Inc Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
DE19722075C1 (de) 1997-05-27 1998-10-01 Wilhelm Dr Med Fleischmann Vorrichtung zur Applikation von Wirkstoffen an einer Wundoberfläche
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
PT1066060E (pt) 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
AU4221399A (en) 1998-05-29 1999-12-13 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
PL366290A1 (en) 1999-11-29 2005-01-24 Hill-Rom Services, Inc. Wound treatment apparatus
EP1290028B1 (en) 2000-06-05 2009-12-23 The Brigham And Women's Hospital, Inc. A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF
AU2002211389A1 (en) 2000-10-03 2002-04-15 California Institute Of Technology Microfluidic devices and methods of use
US6695824B2 (en) 2001-04-16 2004-02-24 The United States Of America As Represented By The Secretary Of The Army Wound dressing system
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US20050186672A1 (en) 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
WO2006103685A2 (en) 2005-03-28 2006-10-05 Vision Research Foundation A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue
IL296832A (en) 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
GB0610778D0 (en) 2006-05-31 2006-07-12 Het Nl Kanker I Phosphatidylinositol phospahte and apoptosis
DK2155248T3 (en) 2007-04-12 2015-09-14 Brigham & Womens Hospital Targeting abcb5 for cancer therapy
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
PT3130923T (pt) 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Métodos terapêuticos relacionados com células estaminais
WO2010065711A1 (en) 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
GB0908927D0 (en) * 2009-05-22 2009-07-01 Univ Reading The Synthetic graft
US20140309738A1 (en) 2011-06-01 2014-10-16 The Board Of Trustees Of The University Of Illinois Membrane-Scaffold Composites for Tissue Engineering Applications
AU2014219026B2 (en) * 2013-02-19 2018-11-29 Children's Medical Center Corporation ABCB5(+) stem cells for treating ocular disease
EP4008369A1 (en) 2013-05-10 2022-06-08 Children's Medical Center Corporation Wound healing and tissue engineering
WO2016179576A1 (en) 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080003206A1 (en) * 2006-05-31 2008-01-03 The Brigham And Women's Hospital, Inc. ABCB5 positive mesenchymal stem cells as immunomodulators

Also Published As

Publication number Publication date
US20150374756A1 (en) 2015-12-31
JP2019189600A (ja) 2019-10-31
US9801912B2 (en) 2017-10-31
US20220118024A1 (en) 2022-04-21
US20180064762A1 (en) 2018-03-08
AU2014219026A1 (en) 2015-09-17
EP3865573A1 (en) 2021-08-18
KR20220048048A (ko) 2022-04-19
US11129854B2 (en) 2021-09-28
KR102385934B1 (ko) 2022-04-13
JP2016510727A (ja) 2016-04-11
EP2964238A1 (en) 2016-01-13
DK2964238T3 (da) 2021-03-22
ES2860573T3 (es) 2021-10-05
JP7027026B2 (ja) 2022-03-01
AU2014219026B2 (en) 2018-11-29
EP2964238B1 (en) 2021-01-13
CA2901931C (en) 2023-03-07
WO2014130518A1 (en) 2014-08-28
KR20160033068A (ko) 2016-03-25
EP2964238A4 (en) 2016-09-07
CA2901931A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
KR102474489B1 (ko) 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포
Ksander et al. ABCB5 is a limbal stem cell gene required for corneal development and repair
Bull et al. Human Muller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration
ES2527444T5 (es) Células del epitelio pigmentario de la retina derivadas de células madre
JP6920363B2 (ja) 多機能未成熟歯髄幹細胞および療法適用
Sun et al. Retinal stem/progenitor properties of iris pigment epithelial cells
Rabesandratana et al. Generation of a transplantable population of human iPSC-derived retinal ganglion cells
CN114245741A (zh) 高功能性的制造的abcb5+间充质干细胞
Thumann et al. Phagocytosis of rod outer segments by human iris pigment epithelial cells in vitro
CN104136601A (zh) 人视网膜祖细胞的表型谱
JP2025020312A (ja) 多能性幹細胞由来の臨床グレードの角膜内皮細胞の作製および凍結保存
US9061017B2 (en) Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
KR20170093178A (ko) 전구 세포를 사용한 안구 질환의 치료
US10039790B2 (en) Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
CN109414460A (zh) 使用祖细胞治疗视网膜血管病
US20240207483A1 (en) Therapeutic Drug for Disease Accompanied by Disorders in Retinal Cells or Retinal Tissue
CN108291199A (zh) 使用祖细胞治疗视网膜变性
Hirata Generation, Purification and Transplantation of Photoreceptors Derived from Human Induced Pluripotent Stem Cells
Ho Photoreceptor Transplantation to the Retina to Investigate Intercellular Communication
O'Malley et al. Monoclonal antibody substrates facilitate long-term regenerative growth of adult primate retinal neurons
Penna UNDERSTANDING AND PROMOTING THE FUNCTIONAL INTEGRATION OF NEURAL TRANSPLANTS IN PARKINSON’S
Del Priore et al. Cellular transplantation for advanced age-related macular degeneration
Rodríguez-cabello et al. Elastin-like recombinamers as substrates for retinal pigment epithelial cell growth
Sands Thymic epithelial cell transplantation to the host thymus: Studies in immunomodulation and tolerance induction
Kawasaki et al. JOS. April 2006, Vol. 47. No. 4

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4